Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan-Feb;99(1):59-64.
doi: 10.1016/j.jped.2022.05.004. Epub 2022 Jul 19.

Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients

Bárbara de Oliveira Silva  1 , Jonathan Wagner Medeiros  2 , Giwellington Silva Albuquerque  2 , Pavel Medina Valderrama  3 , Athos Henrique de Quevedo Barbosa  4 , Juliana Maria de Souza  3 , Renata Santos Oliveira  3 , Adriana Lins Morais  5 , Jacinto da Costa Silva Neto  4 , Maria Tereza Cartaxo Muniz  6
Affiliations

Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients

Bárbara de Oliveira Silva et al. J Pediatr (Rio J). 2023 Jan-Feb.

Abstract

Objective: The aim of our study was to evaluate the expression of MMP-2 and MMP-9 as a prognostic factor in patients diagnosed with Hodgkin Lymphoma (HL).

Methods: In the present study, 45 paraffin biopsies from patients up to 19 years old diagnosed with HL were used in two referral hospitals in the state of Pernambuco, Brazil. Risk groups were classified into favorable and unfavorable, according to Ann Arbor. The expression of matrix metalloproteinases 2 and 9 and their inhibitors was performed by immunohistochemistry (IHC). Data were analyzed using the GraphPad Prism 5 program.

Results: MMP-2 intensity pattern was stronger (>10% of the total field) in patients with stage III/IV and B symptoms. MMP-2 showed an association with the risk group (p = 0.0388). That is, the stronger the MMP-2 marking, the greater the unfavorable risk. However, for MMP-9 there was no difference in the stronger intensity pattern in relation to stages I/II and III/IV, only in the presence of B symptoms. MMP-9 showed an association with B Symptoms (p = 0.0411). Therefore, patients with B symptoms have higher MMP-9 expression.

Conclusion: Our results suggest that MMP-2 expression is associated with HL progression. While MMP-9 expression is related to the clinical worsening of these patients. However, further studies are needed to evaluate the exact role of these proteins in hematologic malignancies.

Keywords: Hodgkin's lymphoma; Matrix metalloproteinases; Prognosis; Risk factor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare no conflicts of interest.

Figures

Fig 1
Figure 1
Representation of positive intensity for proteins and their inhibitors in HL tissue. Arrows indicate: expression of MMP-2 (A), MMP-9 (B), TIMP-1 (C) and TIMP-2 (D). AxioVisio ZEISS® 10x.
Fig 2
Figure 2
Distribution of MMP-2 marking patterns in relation to the clinical risk group.
Fig 3
Figure 3
Distribution of MMP-9 marking patterns in relation to the presence of B symptoms.
See this image and copyright information in PMC

References

    1. Mozaheb Z. Epidemiology of Hodgkin's lymphoma. Health (Irvine Calif) 2013;5:17–22.
    1. Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012;122:3439–3447. - PMC - PubMed
    1. Padera TP, Meijer EF, Munn LL. The lymphatic system in disease processes and cancer progression. Annu Rev Biomed Eng. 2016;18:125–158. - PMC - PubMed
    1. Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:434–442. - PubMed
    1. Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4:151–174. - PubMed

Publication types